Click here to read this study in Lancet Oncology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Click to read this study in the Journal of Clinical Oncology.
1. Atezolizumab plus capecitabine + bevacizumab performed marginally better with regards to progression free survival in patients with metastatic colorectal ...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
Image: PD 1. There is no significant difference in treating advanced gastric cancer refractory to chemotherapy with Paclitaxel or Irinotecan. ...
